RPRX
Royalty Pharma plc · Healthcare · Medical - Pharmaceuticals
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -3.1% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 144 | 0 | 302.77M | $16.97B | +5 | −6 |
| Q1 2026 | 148 | +6 | 297.67M | $14.26B | +10 | −5 |
| Q4 2025 | 141 | +1 | 305.31M | $11.80B | +2 | — |
| Q3 2025 | 19 | +1 | 173.40M | $6.12B | +2 | −2 |
| Q2 2025 | 16 | 0 | 158.26M | $5.71B | — | — |
| Q1 2025 | 13 | -3 | 61.13M | $1.91B | — | −3 |
| Q4 2024 | 16 | +2 | 77.30M | $1.97B | +2 | — |
| Q3 2024 | 13 | -1 | 62.78M | $1.78B | +1 | −2 |
| Q2 2024 | 14 | — | 58.59M | $1.54B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 40.36M | — | $1.45B | 0.1% | n/c | 1 | SEC ↗ ×7 |
| 2 | The Vanguard Group ✦ (passive) | 36.38M | — | $1.31B | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | BlackRock ✦ (passive) | 25.43M | — | $916.20M | 0.0% | n/c | 1 | SEC ↗ ×21 |
| 4 | Baillie Gifford ✦ | 18.02M | +34.5% | $649.28M | 0.5% | ▲ Add | 5 | SEC ↗ ×4 |
| 5 | State Street Global Advisors ✦ (passive) | 10.19M | +7.1% | $367.32M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 8.18M | +2.2% | $299.49M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Adage Capital Partners ✦ | 6.00M | -4.0% | $216.18M | 0.4% | ▼ Trim | 5 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 5.03M | +2.9% | $181.39M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Arrowstreet Capital ✦ | 2.98M | +118.7% | $107.24M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 10 | Viking Global Investors ✦ | 2.60M | -75.4% | $93.59M | 0.3% | ▼ Trim | 5 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 1.74M | -33.4% | $62.15M | 0.1% | ▼ Trim | 5 | SEC ↗ ×5 |
| 12 | Citadel Advisors ✦ | 527.29K | -74.5% | $19.00M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 13 | Millennium Management ✦ | 466.43K | +50.9% | $16.81M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 277.19K | +2.9% | $9.99M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 15 | Two Sigma Investments ✦ | 54.10K | -96.7% | $1.95M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 33.80K | -87.8% | $1.22M | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 583 holders, 354.58M shares, $16.55B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.13K sh · $238,813
Officer · 96.07K sh · $5.62M
Officer · 3.93K sh · $231,403
Officer · 100.00K sh · $6.00M
Officer · 9.23K sh · $540,752
Officer · 1.77K sh · $104,799
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
18.7% of class · View original SEC filing ↗
4.8% of class · View original SEC filing ↗